Committee MemberEmploymentConsultantSpeakers BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Gordon F. Tomaselli, ChairJohns Hopkins School of Medicine—Chief of CardiologyNoneNoneNoneNoneNoneNone
Kenneth W. Mahaffey, Vice ChairStanford Center for Clinical Research—Director; Stanford Department of Medicine—Vice-Chair of Clinical Research, Department of Medicine Stanford Center for Clinical Research
  • Ablynx

  • AstraZeneca

  • Boehringer Ingelheim Pharmaceuticals

  • GlaxoSmithKline

  • Janssen Pharmaceuticals

  • Portola

NoneNoneNone
  • AstraZeneca

  • Verily (Google)

None
Adam CukerUniversity of Pennsylvania—Assistant Professor and Pathology & Laboratory MedicineNoneNoneNoneNoneNoneNone
Paul P. DobeshUniversity of Nebraska Medical Center—AQ Cardiology Professor of Pharmacy Practice, College of Pharmacy
  • AstraZeneca

  • Boehringer Ingelheim

  • Daiichi Sankyo

  • Janssen Pharmaceuticals

  • Pfizer

NoneNoneNoneNoneNone
John U. DohertyJefferson Medical College of Thomas Jefferson University—Professor of MedicineNoneNoneNoneNoneNoneNone
John W. EikelboomMcMaster University—Associate Director, Department of Medicine
  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • Daiichi Sankyo

  • GlaxoSmithKline

  • Pfizer

NoneNone
  • Boehringer Ingelheim

NoneNone
Roberta FloridoJohns Hopkins School of Medicine—Fellow in Cardiovascular MedicineNoneNoneNoneNoneNoneNone
William HuckerMassachusetts General Hospital—Fellow in Cardiovascular MedicineNoneNoneNoneNoneNoneNone
Roxana MehranMount Sinai Medical Center—Professor of Medicine
  • Janssen Pharmaceuticals

NoneNone
  • AstraZeneca

  • Bristol Myers Squibb

  • CSL Behring

NoneNone
Steven R. MesséUniversity of Pennsylvania—Associate Professor of NeurologyNoneNoneNoneNoneNoneNone
Charles V. Pollack, Jr.Thomas Jefferson University Hospital—Professor of Emergency Medicine and Associate Provost
  • AstraZeneca

  • Boehringer Ingelheim

  • Daiichi Sankyo

  • Janssen Pharmaceuticals

  • Pfizer

NoneNone
  • AstraZeneca

  • Boehringer Ingelheim

  • Daiichi Sankyo

  • Janssen Pharmaceuticals

  • Portola

  • CSL Behring

NoneNone
Fatima RodriguezStanford University Medical Center–Fellow in Cardiovascular MedicineNoneNoneNoneNoneNoneNone
Ravindra SarodeUniversity of Texas Southwestern—Professor of Pathology, Chief of Pathology and Medical Director of Clinical Laboratory Services, UT Southwestern Medical Center, and Director, Transfusion Medicine and Hemostasis
  • CSL Behring

  • Portola

NoneNoneNoneNoneNone
Deborah SiegalMcMaster University—Clinical Scholar, Division of Hematology and Thromboembolism
  • Bristol-Myers Squibb/Pfizer

NoneNoneNone
  • Portola

None
Barbara S. WigginsMedical University of South Carolina—Clinical Pharmacy Specialist, Cardiology Department of Pharmacy ServicesNoneNoneNoneNoneNoneNone

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

ACC = American College of Cardiology; SCAI = Society for Cardiac Angiography and Interventions.

  • Significant relationship.

  • No financial benefit.